Poliquistosis renal autosómica dominante: ¿quiénes se benefician del tratamiento con tolvaptán? Estado del arte

Abstract

Autosomal dominant polycystic kidney disease is the most common hereditary kidney disease. It is charac - terized by the progressive appearance of renal cysts that usually lead to extreme chronic kidney disease in adulthood. The approval of the use of tolvaptán (V2 va-sopressin receptor antagonist) has meant a significant change in the treatment of this disease. In recent years, evidence has proved the benefits of initiating treatment with tolvaptán in patients with a rapidly evolving disease. A descriptive review of the main clinical studies published in 2012-2022 period is carried out and a use-ful scheme is suggested to select